413 related articles for article (PubMed ID: 33927196)
1. Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM; Fonseca R; Usmani SZ
Blood Cancer J; 2021 Apr; 11(4):83. PubMed ID: 33927196
[TBL] [Abstract][Full Text] [Related]
2. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
3. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.
Balcárková J; Urbánková H; Scudla V; Holzerová M; Bacovský J; Indrák K; Jarosová M
Cancer Genet Cytogenet; 2009 Jul; 192(2):68-72. PubMed ID: 19596256
[TBL] [Abstract][Full Text] [Related]
4. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
Neupane K; Fortuna GG; Dahal R; Schmidt T; Fonseca R; Chakraborty R; Koehn KA; Mohan M; Mian H; Costa LJ; Sborov D; Mohyuddin GR
Blood Cancer J; 2024 Jan; 14(1):20. PubMed ID: 38272897
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature.
Barbieri E; Martino EA; Rivolti E; Quaresima M; Vigna E; Neri A; Morabito F; Gentile M
Expert Opin Biol Ther; 2024 May; 24(5):365-381. PubMed ID: 38757726
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
[TBL] [Abstract][Full Text] [Related]
8. Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.
Burroughs Garcìa J; Eufemiese RA; Storti P; Sammarelli G; Craviotto L; Todaro G; Toscani D; Marchica V; Giuliani N
Cells; 2021 Jun; 10(6):. PubMed ID: 34205916
[TBL] [Abstract][Full Text] [Related]
9. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target.
Luo S; Su T; Zhou X; Hu WX; Hu J
FASEB J; 2022 Jun; 36(6):e22341. PubMed ID: 35579877
[TBL] [Abstract][Full Text] [Related]
15. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Sawyer JR; Tian E; Heuck CJ; Johann DJ; Epstein J; Swanson CM; Lukacs JL; Binz RL; Johnson M; Sammartino G; Zangari M; Davies FE; van Rhee F; Morgan GJ; Barlogie B
Blood; 2015 Jun; 125(24):3756-9. PubMed ID: 25943786
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Locher M; Steurer M; Jukic E; Keller MA; Fresser F; Ruepp C; Wöll E; Verdorfer I; Gastl G; Willenbacher W; Weger R; Nachbaur D; Wolf D; Gunsilius E; Zschocke J; Steiner N
Am J Hematol; 2020 Dec; 95(12):1562-1571. PubMed ID: 32936982
[TBL] [Abstract][Full Text] [Related]
17. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.
Sawyer JR; Tricot G; Mattox S; Jagannath S; Barlogie B
Blood; 1998 Mar; 91(5):1732-41. PubMed ID: 9473240
[TBL] [Abstract][Full Text] [Related]
18. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.
Sawyer JR; Tricot G; Lukacs JL; Binz RL; Tian E; Barlogie B; Shaughnessy J
Genes Chromosomes Cancer; 2005 Jan; 42(1):95-106. PubMed ID: 15472896
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
Abdallah N; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Rajkumar SV; Kumar SK
Blood Adv; 2020 Aug; 4(15):3509-3519. PubMed ID: 32750129
[TBL] [Abstract][Full Text] [Related]
20. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
[Next] [New Search]